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translate into protective effects against
vascular calcification.
Despite these caveats, the study by
Lau et al.8 is important, as it adds a new
dimension to the beneficial effects of
active vitamin D on the vasculature in
patients with CKD—who are in a state
of Klotho deficiency.7 The results of this
study highlight the need to determine
whether an optimal dose of active
vitamin D is a panacea for vascular
calcification in patients with CKD and, if
so, whether secreted Klotho is involved
in this beneficial effect of active vitamin
D. Clearly, there is still much to learn
about the role of vitamin D and secreted
Klotho in the pathogenesis of vascular
calcification in CKD, and much more
work is needed to translate the findings
of this study into clinical practice in
patients with CKD.
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Autophagy protects proximal
tubular cells from injury and
apoptosis
Gur P. Kaushal1,2,3
Autophagy is upregulated during ischemia–reperfusion (IR)-induced
and cisplatin-induced acute kidney injury (AKI). Proximal tubule-specific
Atg7 knockout mice exhibited increased renal injury compared with
wild-type mice following cisplatin- and IR-induced AKI. Inhibition of
autophagy by chloroquine aggravated AKI, whereas upregulation of
autophagy by rapamycin recovered lost renal function and histology,
further indicating a protective role of autophagy in AKI. These findings
reported by Jiang et al. will provide stimulus to further examine the
role and mechanism of the enhancement of autophagy in AKI.
Kidney International (2012) 82, 1250–1253. doi:10.1038/ki.2012.337
Autophagy is a catabolic process of
degradation of long-lived proteins,
cellular macromolecules, and intracel-
lular organelles through the lysosomal
hydrolases. In this process, a double-
membrane structure known as an
autophagosome sequesters and delivers
cytoplasmic contents to the lysosome
for degradation. Free amino acids and
fatty acids generated on degradation of
cellular components are recycled to
synthesize new proteins and bioener-
getic supplies of the cell. Thus, under
normal physiological conditions, basal
autophagy plays a homeostatic role that
maintains cellular homeostasis and
quality control. Autophagy is induced
in response to stress conditions includ-
ing cell starvation, growth factor depri-
vation, hypoxia, and oxidant injury.
Under stress conditions, autophagy
induction is generally considered to
play an adaptive role that ensures cell
survival. The molecular machinery in-
volved in autophagosome formation is
composed of evolutionarily conserved
Atg-related proteins originally identi-
fied in yeast.1 The formation of an
autophagosome is initiated by several
autophagic protein complexes, includ-
ing the unc-51-like kinase 1 or 2
(ULK1 or ULK2) complex, the class
III phosphatidylinositol 3-kinase com-
plex, Atg12–Atg5–Atg16 conjugation,
and lipidation of microtubule-asso-
ciated protein 1 light chain 3 (LC3)
with phosphatidylethanolamine to form
LC3-II1 (Figure 1). The elongation and
expansion steps in autophagosome for-
mation involve two ubiquitin-like pro-
teins, Atg12 and Atg8/LC3 (Figure 1).
The conjugation of Atg12 to Atg5 is
catalyzed by Atg7 and Atg10 (E1- and
E2-like enzymes, respectively) to form
covalently linked Atg12–Atg5. Follow-
ing formation of the Atg12–Atg5
conjugate, Atg16L non-covalently asso-
ciates with this conjugate to produce
the Atg12–Atg5–Atg16 multimeric com-
plex.1 At present, there is great interest
in studying autophagy under various
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pathological conditions, including renal
diseases, partly because of the recogni-
tion that autophagy is an evolutionarily
conserved process and its activation may
play a pro-survival role. Atg knockout
mice were originally considered to be
used in evaluating the specific role
of autophagy in mammalian cells;
however, most of the Atg knockout
mice showed embryonic or neonatal
lethality.2 Tissue-specific Cre-lox-based
conditional Atg knockout mice are now
being generated to directly evaluate the
specific role of autophagy in disease
conditions.
Jiang et al.3 (this issue) report that
proximal tubule-specific Cre-lox-based
Atg7 knockout mice exhibited increased
renal injury compared with wild-type
mice in response to cisplatin-induced
and ischemia–reperfusion (IR)-induced
acute kidney injury (AKI). The prox-
imal tubule-specific Atg7 knockout
mice were normal at birth and did
not show any overt phenotype in
kidneys. Atg7 deletion was unable to
produce autophagosomes in proximal
tubules, since the Atg12–Atg5–Atg16
multimeric complex required for
autophagosome biosynthesis is not
formed in the absence of Atg7. Inhibi-
tion of autophagy by chloroquine
administration worsened AKI, whereas
upregulation of autophagy by rapamy-
cin treatment ameliorated cisplatin
nephrotoxicity. These findings are in
close agreement with the recently
published reports on the pro-survival
role of autophagy in renal IR injury4,5
and cisplatin nephrotoxicity6 in tubule-
specific Atg5 knockout mice. One of the
interesting findings from Atg7- or
Atg5-deficient kidneys is the rapid
accumulation of p62 and formation of
p62-positive inclusion bodies. p62, also
known as sequestosome 1 (SQSTM1)
or A170, is one of the key autophagy
substrates. The expression levels of p62
can be used to assess autophagic flux in
some contexts. In an efficient flux of
the autophagic pathway, p62 interacts
with LC3 through its LC3-interacting
domain that enables incorporation
of p62 and p62-bound polyubiquitinated
protein aggregates into the auto-
phagosome, where p62–LC3 complex
and bound aggregates are subsequently
degraded by the lysosome. However,
during inactivation of autophagy such
as in Atg7- or Atg5-deficient kidneys or
during impaired autophagic flux, p62
cannot be degraded by the autophagy-
lysosomal pathway and is accumulated.
Also, p62 and associated aggregates are
often found in cytoplasmic inclusion
bodies that are composed of misfolded
proteins and damaged organelles. A
recent study has shown an inhibitory
effect of accumulated p62 and asso-
ciated polyubiquitinated protein aggre-
gates on the ubiquitin–proteasome
system.7 Therefore, further studies are
needed to establish whether p62 aggre-
gates compromise the impact of the
ubiquitin–proteasome system in Atg-
deficient kidneys. Another remarkable
finding of Jiang et al.3 is that Atg5
deletion in proximal tubules results in
accumulation of oxidative stress markers
and increased proximal tubule apopto-























Figure 1 | The autophagy pathway and autophagic flux. Autophagosome assembly in the autophagy pathway follows a series of steps. The
process of autophagy begins in the cytoplasm by formation of a double-membrane structure, phagophore, or isolation membrane that has
sequestered or engulfed the targeted portion of the cytoplasm, containing misfolded proteins, damaged macromolecules, and organelles. The
‘core’ autophagic machinery uses Atg proteins for the formation of the phagophore, and its subsequent elongation to mature autophagosome
formation proceeds through a series of steps mediated by several functional protein complexes: (1) The ULK1/2 kinase complex is required for
the induction of autophagy and participates at the site of autophagosome formation. The ULK1/2 (Atg1) complex is composed of ULK1/2,
Atg13, FIP200, and Atg101. ULK1/2 is negatively regulated by mTORC1. (2) A class III phosphatidylinositol 3-kinase complex is required for
nucleation of the phagophore membrane. Beclin1 (Atg6) and Atg14 are part of this complex. (3) The elongation and expansion steps in
autophagosome formation involve two conjugation systems that require ubiquitin-like proteins, Atg12 and Atg8/LC3-II. Transmembrane Atg9
facilitates this step. The first conjugation system is facilitated by Atg7 and Atg10, which conjugate Atg12 to an internal lysine of Atg5. The
Atg5–Atg12 conjugate subsequently associates non-covalently with Atg16 to form an Atg12–Atg5–Atg16 multimeric complex. The second
conjugation step is the formation of LC3-II (Atg8-PE) by conjugation of LC3 with phosphatidylethanolamine (PE). The two conjugation systems
are recruited to the phagophore membrane for phagophore expansion to complete the formation of the autophagosome. Once the
autophagosome is formed, most of the Atg proteins are dissociated, which allows fusion with the lysosome to form the autolysosome. LC3-II
remains present in both the membranes of the autophagosome. The sequestered contents and the inner membrane of the autolysosome are
degraded by the lysosomal hydrolases. Autophagic flux is an indicator that the autophagy process has been completed. AA, amino acids;
FA, fatty acids; PI, phosphatidylinositol.
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in the increased production of oxidants
and apoptosis due to Atg5 or Atg7
deletion needs to be examined further.
Autophagy is vital for the kidney, and
accumulating evidence has shown
upregulation of autophagy in in vitro
and in vivo experimental models of both
AKI8–10 and chronic kidney disease.
Many of these studies used pharma-
cological inhibitors of autophagy to
delineate whether autophagy induction
plays a pro-survival or a pro-death role.
These studies provided initial informa-
tion on the upregulation and role of
autophagy in AKI. However, to directly
determine the role of autophagy in AKI
or chronic kidney disease, tissue-specific
autophagy-deficient mice or tissue-
specific overexpression of autophagy
protein components that enhance auto-
phagy in mice are required. Jiang and
colleagues,3 by using proximal tubule-
specific Atg7-deficient mice, validated
previous studies that showed a pro-
survival role of autophagy in AKI.
Further investigation by Jiang et al.3
demonstrated that administration of
the lysosomotropic agent chloroquine
impairs autophagic flux in cisplatin
nephrotoxicity as shown by the
accumulation of LC3-II and p62. At
present, the efficiency of the auto-
phagy-lysosomal degradation pathway
is not known in AKI. Even a detailed
time-course study on the activation of
autophagy during the course of
ischemic, reperfusion, or regeneration
periods is not yet completely establi-
shed. Since efficient flux is critical for
cell survival, more careful studies are
required for measurement of autopha-
gic flux during IR and cisplatin injury.
Efficient autophagic flux is dependent
on the integrity of the lysosomes and
their appropriate fusion with the
autophagosomes. It may be necessary
to critically assess lysosomal dysfunc-
tion in the pathogenesis of AKI. Thus,
more studies are needed to understand
alterations in the lysosomal membrane
permeabilization similarly to what we
now know about the mitochondrial
membrane permeabilization in AKI.
The process of the fusion of the lyso-
some with the autophagosome is also
important for efficient lysosomal
function in the clearance of the
autophagosome cargo. Thus, the inte-
grity of the lysosomal membranes and
their fusion with the autophago-
somes are important determinants in
efficient autophagic flux during AKI.
At present, the mechanism of in-
duction of autophagy in AKI is not
clearly understood. AKI may result
from various pathological conditions,
including oxidative stress, endoplasmic
reticulum stress, mitochondrial and
other intracellular organelle damage,
DNA damage, and inflammation, all
of which can activate and affect auto-
phagy. Thus diverse signaling pathways
involved in each of these conditions
may be involved in activation of
autophagy during AKI. Jiang et al.3
show that in response to cisplatin-
induced AKI, proximal tubule-specific
Atg7 knockout mice exhibited increased
activation of p53 and c-Jun N-terminal
kinase. Further studies will be required
to understand the effect of Atg7
deletion or autophagy deficiency on
these pathways. Jiang et al.3 also show
that administration of rapamycin
provides protection from cisplatin-
induced AKI. However, care should be
used in interpreting the results
obtained with rapamycin. Rapamycin
has been used commonly as an inducer
of autophagy by virtue of its inhibition
of mTORC1 kinase. Inhibition of
mTORC1 kinase or inactivation of
mTORC1 leads to activation of the
first autophagy protein, ULK1/2 (yeast
Atg1), which upregulates autophagy,11
and this induction of autophagy was
shown in kidney cells on inhibition of
mTOR kinase by rapamycin. However,
the nutrient-sensing molecule mTOR is
also an important regulator of cell
growth and proliferation. Inhibition of
mTOR may upregulate autophagy,
and it may affect other vital processes
in the cell. Therefore, rapamycin’s
effect on autophagy induction and cell
survival should be carefully evaluated.
Previous studies have shown that
mTOR is upregulated in AKI, and
inhibition of mTOR by rapamycin is
associated with a delay in recovery from
AKI.12 Also, recent studies have shown
that rapamycin is a poor inhibitor of
mTOR and may not be very effective in
inducing autophagy. Therefore, as an
alternative to rapamycin, a genetic
approach that specifically augments
autophagy may offer a better tool to
evaluate the role of autophagy in AKI.
Current studies have examined the role
of autophagy by inhibiting it through
pharmacological inhibitors or by down-
regulating it with genetic approaches. It
will be useful to investigate the role of
autophagy in AKI by enhancing it using
genetic approaches.
The work presented by Jiang and
colleagues3 provides direct evidence
for a renoprotective role of autophagy
in AKI. The findings highlight the
importance of delineating the mecha-
nisms involved in the upregulation
and cytoprotective role of autophagy.
Further studies will help in identifying
autophagy or a specific event in the
autophagic pathway as a therapeutic
tool to prevent or reduce AKI.
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Thomas Mueller1 and Benjamin Dieplinger1
According to a proposed concept of a gastrointestinal–renal natriuretic
signaling axis, natriuretic peptides are released from the intestine into
the circulation in response to oral salt intake and act on the kidneys as
hormones to increase sodium excretion. The peptides guanylin and
uroguanylin and their precursors proguanylin and prouroguanylin,
respectively, have been suggested to be the mediators of this axis.
A study by Preston and co-workers, however, provides important
data not supporting this putative concept.
Kidney International (2012) 82, 1253–1255. doi:10.1038/ki.2012.344
Studies in the 1970s demonstrated that
an oral load of sodium evoked higher
natriuresis than did a similar intrave-
nous load of sodium in humans.1,2
These observations have contributed
to the concept of a gastrointestinal–
renal natriuretic signaling axis. Accord-
ing to this concept, natriuretic peptides
are released from the intestine into the
circulation in response to oral salt
intake and thereafter act on the kidneys
as hormones to increase sodium excre-
tion. During the past 20 years, two
members of the guanylin peptide
family, guanylin and uroguanylin, have
been suggested as candidates for mediat-
ing this proposed postprandial entero-
renal endocrine axis.3,4 However,
Preston et al.5 (this issue) now pro-
vide results from a high-quality experi-
mental study in healthy subjects that do
not support the existence of such an
acute gastrointestinal–renal natriuretic
signaling axis. Most importantly, the
authors of this work cast doubt on a
central role of guanylin peptide family
members in such an axis if it really
exists.
The guanylin peptide family has
several subclasses of peptides, including
guanylin and uroguanylin.6 The sources
of these peptides are the intestine and
the kidneys but also other epithelia.
Guanylin mRNA has been detected
mainly in the gastrointestinal tract in
numerous cell types and in the kidney.
Uroguanylin mRNA is, for example,
present in the gut, kidney, heart,
reproductive system, and brain. The
expression pattern of both peptides is
differential in the intestine: the highest
expression of guanylin occurs in the
ileum to the proximal colon, and of
uroguanylin in the jejunum.6 As in the
gut, guanylin and uroguanylin are not
equally expressed along the different
nephron segments. Guanylin is more
pronounced in the collecting duct, and
uroguanylin is present mostly in the
proximal tubule.6 In the classical point
of view, guanylin and proguanylin are
primarily thought to participate in the
regulation of salt and water homeostasis
in the intestine and the kidney.3,4,6
Guanylin peptides produced in the
intestine after ingestion of a salty meal
are secreted into the intestinal lumen.
In the intestine, guanylin and urogua-
nylin activate epithelial cells mainly
via the guanylate cyclase C receptor
with cyclic guanosine monophosphate
(cGMP) as second messenger.3,4,6
Activation of this pathway leads to the
secretion of Cl and HCO3
 and to
the inhibition of Naþ absorption,
which drives water secretion into the
intestinal lumen.4,6 These mechanisms
are probably involved in the regulation
of salt and water transport across the
intestinal epithelia and in the regu-
lation of intestinal pH. In addition,
guanylin and uroguanylin target the
renal tissue, eliciting natriuresis, kali-
uresis, and diuresis, along with increas-
ing urinary cGMP levels without
changes in glomerular filtration rate
or renal blood flow.3,4,6 Thus, guanylin
peptides presumably induce increased
urinary salt and water excretion in
order to prevent hypernatremia and
hypervolemia after enhanced salt
uptake exceeding the body’s physio-
logical requirements. In contrast to the
intestine, where the guanylate cyclase C
receptor seems to be the most important
receptor by far, guanylin and uroguany-
lin can activate different pathways along
the nephron. The guanylate cyclase C
receptor has been suggested to play a
minor role in the kidney, conceivably
restricted to the proximal tubule. In
the kidney, additional receptors with
different messenger systems are
activated by the guanylin peptides and
mediate complex effects on electrolyte
and water excretion.3,4,6 The molecular
identities of these renal receptors for
1Department of Laboratory Medicine,
Konventhospital Barmherzige Brueder Linz, Linz,
Austria
Correspondence: Thomas Mueller, Department of
Laboratory Medicine, Konventhospital Barmherzige
Brueder, Seilerstaette 2-4, Linz A-4020, Austria.
E-mail: thomas.mueller@bs-lab.at
Kidney International (2012) 82 1253
commentary
